Please ensure Javascript is enabled for purposes of website accessibility

Moderna to Test Coronavirus Vaccine Booster Shot in New Clinical Trial

By Eric Volkman - Jan 14, 2021 at 11:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company wants to see if it can still produce a sufficient response one year after inoculation.

The first jab of Moderna's (MRNA -3.46%) two-shot coronavirus vaccine hasn't made it into the arms of the millions who will eventually receive it, but the company is already planning to gauge the effectiveness of a booster.

In a presentation at this year's annual J.P. Morgan Healthcare Conference, Moderna said it plans to do so in a clinical trial involving participants of earlier studies of the vaccine, mRNA-1273. It has already begun contacting potential participants, and it plans to begin the study in July.

A patient receiving a vaccination shot.

Image source: Getty Images.

"From what we've seen so far, I think our expectation is that the vaccination should last you at least a year," Moderna Chief Medical Officer Tal Zaks said during the conference. "To the degree that you need a booster shot, we'll make a data-based recommendation, and that will require us getting the data."

In the planned study, Moderna will try to determine the level of immune response still being generated by the booster shot, CEO Stephane Bancel said at the event.

The timing is right for a follow-up study, as the participants in the first clinical trials of the vaccine are nearing their one-year anniversary of receiving the booster. They were given the first shot in the middle of March 2020.

Moderna is one of two coronavirus vaccines that have been granted emergency use authorization by the U.S. Food and Drug Administration. However, the rollouts of mRNA-1273 and Pfizer/BioNTech's similarly two-shot BNT162b2 have been slow. The numbers of patients who have received the first dose remain worryingly low.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$137.35 (-3.46%) $-4.93
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.42 (-1.79%) $0.92
BioNTech SE Stock Quote
BioNTech SE
BNTX
$157.28 (-1.58%) $-2.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.